Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
Loading...
Authors
Radford, J. A.
Clark, S.
Crowther, D.
Shalet, S. M.
Issue Date
1994-02
Type
Article
Language
en_US
Keywords
Male Fertility , Hodgkin's Disease , Chemotherapy
Alternative Title
Abstract
Semen analysis was performed in 14 men a median of 13.5 months after completion of VAPEC-B chemotherapy for Hodgkin's disease or non-Hodgkin's lymphoma. Semen from 12 patients contained motile spermatozoa, and in nine cases the count was > 20 million ml-1. One patient was azoospermic (VAPEC-B followed by pelvic radiotherapy) and another had a count of 21 million ml-1 but sperm were non-motile. These findings suggest that, in the majority of cases, VAPEC-B chemotherapy does not cause permanent damage to the male germinal epithelium. A more detailed study of gonadal function in males and females before and after treatment with VAPEC-B for Hodgkin's disease is currently in progress.
Description
Citation
Radford, J. A., Clark, S., Crowther, D., & Shalet, S. M. (1994). Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma. British journal of cancer, 69(2), 379–381. https://doi.org/10.1038/bjc.1994.69
Publisher
British Journal of Cancer